Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial (Osteoporosis International, 10.1007/s00198-014-2944-6);Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

Osteoporosis International

Volumn 26, Issue 2, 2015, Pages 699-712

  Bone, H G ^a,j   Dempster, D W ^b   Eisman, J A ^c   Greenspan, S L ^d   McClung, M R ^e   Nakamura, T ^f   Papapoulos, S ^g   Shih, W J ^h   Rybak Feiglin, A ⁱ   Santora, A C ⁱ   Verbruggen, N ⁱ   Leung, A T ⁱ   Lombardi, A ⁱ  

^a Michigan Bone and Mineral Clinic   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF NOTRE DAME   (Australia)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e OREGON OSTEOPOROSIS CENTER   (United States)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j ST LUKE S HOSPITAL   (United States)

more..

Author keywords

Cathepsin K; Fracture; Odanacatib; Osteoporosis; Postmenopausal

Indexed keywords

CALCIUM; COLECALCIFEROL; ODANACATIB; PLACEBO; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CATHEPSIN K; CTSK PROTEIN, HUMAN;

AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE RADIOGRAPHY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FRACTURE HEALING; HIP FRACTURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGISTRATION; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SKIN DISEASE; SKINFOLD; SPINE FRACTURE; TOOTH DISEASE; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HIP; METHODOLOGY; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PATIENT SELECTION;

AGED; BIPHENYL COMPOUNDS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CATHEPSIN K; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATIENT SELECTION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84925493847     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3274-z     Document Type: Erratum

References (42)

1. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285; 1: 785-95
2. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229–238
3. Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76–81
4. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Feng X, Van Hul W, Wan M, Cao X (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15:757–765
5. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K (2006) Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111–121
6. Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R (2013) Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 123(1):666–681
7. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(1):337–342
8. Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(5):677–692
9. Heaney RP, Yates AJ, Santora AC (1997) Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12(1):1143–1151
10. Hernandez CJ, Beaupre GS, Marcus R, Carter DR (2001) A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29(1):511–516
11. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29(2):185–191
12. Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59(2):173–179
13. Lewiecki EM (2011) New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 7(1):631–638
14. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 7(1):447–456
15. Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236–1238
16. Duong L (2012) Therapeutic inhibition of cathepsin K—reducing bone resorption while maintaining bone formation. BoneKEy Rep 1:1–8
17. Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J (2001) Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 16:1444–1452
18. Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, Lamontagne S, Masse F, Riendeau D, Toulmond S, Percival MD (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 48(2):7535–7543
19. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Leger S, LeRiche T, Li CS, Masse F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Therien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923–928
20. Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175–182
21. Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, Scott BB, Panebianco D, Ding Y, Gottesdiener K, Wagner JA (2013) Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics—results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol 75:1240–1254
22. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937–947
23. Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242–251
24. Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez PJ, Denker A, Lombardi A, Le Bailly DT, DaSilva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27(1):2251–2258
25. Kanis JA, Alexandre JM, Bone HG, Abadie E, Brasseur D, Chassany O, Durrleman S, Lekkerkerker JF, Caulin F (2003) Study design in osteoporosis: a European perspective. J Bone Miner Res 18(24):1133–1138
26. Clinical trials for new osteoporosis treatments 2002. http://www.fda.gov/ohrms/dockets/ac/cder02 htm#EndocrinologicMetabolicDrugs
27. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
28. Study to evaluate the safety and efficacy of BA058 for prevention of fracture in postmenopausal women 2013. http://www.clinicaltrials.gov/ct2/show/NCT01343004?term=BA-058&rank=3
29. Multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of AMG 785 treatment in postmenopausal women with osteoporosis 2012. http://www.clinicaltrials.gov/ct2/show/NCT01575834?term=AMG+785&rank=13A
30. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(2):1137–1148
31. Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB (2011) Issues in modern bone histomorphometry. Bone 49(1):955–964
32. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(2):2–17
33. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(1):2267–2294
34. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23
35. Miettinen O, Nurminen M (1985) Comparative analysis of two rates. Stat Med 4(2):213–226, 13
36. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57:289–300
37. Hochberg YA (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrica 75:800–802
38. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541
39. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 366:2051–2053
40. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(1):1189–1199
41. Vittinghoff E, McCulloch CE, Woo C, Cummings SR (2010) Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med 29(1):1127–1136
42. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98(1):4483–4492